196 recruiting. 196 Phase 2, 76 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 196 | Recruiting 196 |
| Phase 1 | 76 | Recruiting 76 |
| Phase 3 | 7 | Recruiting 7 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-28 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-10-30 | 2026-10-15 |
| A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma IBI3003 - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fortvita Biologics (USA)Inc. | 360 | 2026-09-30 | 2026-09-25 |
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 38 | 2026-09-30 | 2026-10-05 |
| CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment CM336 Plus Isatuximab - Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 26 | 2026-09-10 | 2026-09-17 |
| A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma CT0596 - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | UCARsgen Biotech Limited | 68 | 2026-09-03 | 2026-09-17 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-10-29 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma anti-BCMA/CD3 bispecific antibody - Multiple Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-07-07 | 2026-08-07 |
| A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma Ramantamig, Tocilizumab, Placebo - Multiple Myeloma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 230 | 2026-06-30 | 2026-10-01 |
| DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia DIAG723, Placebo - Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | Recruiting | Diagonal Therapeutics, Inc. | 93 | 2026-06-04 | 2026-09-08 |
| CAR-T in Relapsed/Refractory Multiple Myeloma CAR-T - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-08 |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Teclistamab - Multiple Myeloma, AL Amyloidosis | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 30 | 2026-05-22 | 2026-08-03 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide - Multiple Myeloma | Phase 2 | Recruiting | Eden Biltibo | 50 | 2026-04-20 | 2026-08-19 |
| To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma SG2918 - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Hangzhou Sumgen Biotech Co., Ltd. | 40 | 2026-04-16 | 2026-07-10 |
Showing 20 of 196. Sign in to see all of them.
Multiple Myeloma (177) · Recurrence (25) · Lymphoma, Non-Hodgkin (13) · Waldenstrom Macroglobulinemia (13) · Neoplasms, Plasma Cell (11) · Neoplasms (10) · Leukemia, Myeloid, Acute (9) · Hematologic Neoplasms (8) · Hodgkin Disease (7) · Leukemia, Plasma Cell (7) · Lymphoma (7) · Lymphoma, B-Cell, Marginal Zone (7) · Myelodysplastic Syndromes (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Follicular (6)
Hemic and Lymphatic Diseases (196) · Cardiovascular Diseases (194) · Hemorrhagic Disorders (194) · Vascular Diseases (194) · Hematologic Diseases (193) · Immune System Diseases (191) · Immunoproliferative Disorders (189) · Blood Protein Disorders (188) · Lymphoproliferative Disorders (188) · Paraproteinemias (188) · Neoplasms by Histologic Type (187) · Neoplasms (180) · Neoplasms, Plasma Cell (179) · Pathologic Processes (44)
Dexamethasone (51) · Lenalidomide (26) · daratumumab (25) · Cyclophosphamide (19) · pomalidomide (19) · Calcium Dobesilate (17) · carfilzomib (15) · Bortezomib (13) · isatuximab (12) · talquetamab (12) · Biopsy (10) · belantamab mafodotin (10) · Specimen Handling (9) · fludarabine (9) · Magnetic Resonance Spectroscopy (8)
Institute of Hematology & Blood Diseases Hospital, China (11) · Memorial Sloan Kettering Cancer Center (7) · M.D. Anderson Cancer Center (6) · Mayo Clinic (6) · National Cancer Institute (NCI) (5) · Regeneron Pharmaceuticals (5) · Janssen Research & Development, LLC (4) · Massachusetts General Hospital (4) · AbbVie (3) · AstraZeneca (3) · BeOne Medicines (3) · SCRI Development Innovations, LLC (3) · Xuzhou Medical University (3) · Cancer Research UK (2) · Chongqing Precision Biotech Co., Ltd (2)
United States (110) · China (55) · Spain (21) · United Kingdom (21) · Australia (18) · Germany (16) · Canada (15) · France (14) · South Korea (13) · Japan (12) · Greece (9) · Israel (9) · Brazil (7) · Italy (7) · Norway (7)
Dickran Kazandjian, MD (3) · Carl O Landgren, MD, PhD (2) · Cheng Qian, PhD (2) · Lugui Qiu (2) · Noopur Raje, MD (2) · Roxana S. Dronca, MD (2) · Sanbin Wang, MD (2) · Ah-Reum Jeong (1) · Ajay K. Nooka, MD,MPH,FACP (1)
PMID 38826786, PMID 25319501, PMID 27412889, PMID 28652319, PMID 30352784, PMID 31910860, PMID 32345372, PMID 33068284, PMID 33090333, PMID 33717057, PMID 33844595, PMID 35285981, PMID 35537408, PMID 35880941, PMID 36315917, PMID 36753688, PMID 36853224, PMID 37027810, PMID 37315265, PMID 37348018, PMID 37393120, PMID 37489819, PMID 37561967, PMID 38039429, PMID 38096472, PMID 38354330, PMID 38402374, PMID 38564684, PMID 38724717, PMID 38748939, PMID 38816232, PMID 38865672, PMID 38879802, PMID 38992129, PMID 39013131, PMID 39155155, PMID 39167092, PMID 39413339, PMID 40090350, PMID 40558019, PMID 40610648, PMID 40629516, PMID 40631904, PMID 40864183, PMID 40938675, PMID 41036677, PMID 41100773, PMID 41144785, PMID 41239440, PMID 41313549
2023 (8), 2025 (6), 2017 (2), U10CA180820 (2), P30CA033572 (1), P30CA138292 (1), P50CA186781 (1), U10CA180888 (1), U54AR057319 (1)